Unnamed: 0 float64 0 336 ⌀ | Ticker stringclasses 2
values | Year stringclasses 8
values | Text stringlengths 4 2.95k | Embedding stringlengths 9 34.6k |
|---|---|---|---|---|
261 | LLY | 2017 | Our effective tax rate was 18.9 percent in 2016, compared with 13.7 percent in 2015. The increase in the effective tax rate for 2016 reflects several factors in both years: in 2016, the unfavorable tax effect of the charge related to the impact of the Venezuelan financial crisis and certain asset impairment, restructur... | [-0.040495865046978, 0.0026976745575666428, 0.0076447599567472935, -0.05175910145044327, -0.010719493962824345, -0.022487632930278778, 0.005861414130777121, -0.011826397851109505, -0.01768457517027855, -0.029154952615499496, 0.007094544358551502, 0.017451543360948563, 0.013956055976450443, 0.005181735847145319, -0.0068... |
262 | LLY | 2017 | As of December 31, 2017, cash and cash equivalents was $6.54 billion, an increase of $1.95 billion, compared with $4.58 billion at December 31, 2016. Refer to the Consolidated Statements of Cash Flows for additional details on the significant sources and uses of cash for the years ended December 31, 2017 and December 3... | [-0.019324788823723793, -0.01646742783486843, -0.01219391729682684, -0.012551087886095047, -0.003128372598439455, -0.002811932237818837, -0.009512007236480713, -0.011015881784260273, -0.01460011675953865, -0.01159236766397953, 0.03694518655538559, 0.007456711959093809, -0.01804649643599987, 0.009787717834115028, 0.0142... |
263 | LLY | 2017 | In addition to our cash and cash equivalents, we held total investments of $7.18 billion and $6.66 billion as of December 31, 2017 and December 31, 2016, respectively. See Note 7 to the consolidated financial statements for additional details. | [-0.006319266278296709, -0.030581187456846237, -0.0008914226200431585, -0.01295576523989439, -0.02087388187646866, 0.006319266278296709, -0.03289064019918442, -0.0005971897044219077, 0.01875477097928524, 0.00450787041336298, 0.018818216398358345, 0.02145758830010891, -0.013831325806677341, 0.007677020505070686, 0.01957... |
264 | LLY | 2017 | As of December 31, 2017, total debt was $13.65 billion, an increase of $3.34 billion compared with $10.31 billion at December 31, 2016. The increase was primarily due to the cash proceeds of $2.23 billion from the issuance of fixed-rate notes and, to a lesser extent, the net increase in the balance of commercial paper ... | [-0.028840648010373116, -0.0023922014515846968, 0.0042314957827329636, -0.018920283764600754, -0.011058138683438301, -0.014458675868809223, -0.02082509547472, 0.01054677926003933, -0.011448049917817116, -0.006232188083231449, 0.032548002898693085, 0.017335070297122, -0.020275384187698364, 0.006583747453987598, -0.00066... |
265 | LLY | 2017 | For the 132nd consecutive year, we distributed dividends to our shareholders. Dividends of $2.08 per share and $2.04 per share were paid in 2017 and 2016, respectively. In the fourth quarter of 2017, effective for the dividend to be paid in the first quarter of 2018, the quarterly dividend was increased to $0.5625 per ... | [-0.032208461314439774, -0.0003397382970433682, -0.019380958750844002, -0.04335949569940567, -0.00928406324237585, -0.00668046111240983, -0.019368257373571396, -0.003530738176777959, -0.013094211928546429, -0.00693447096273303, 0.0044229477643966675, 0.021755950525403023, 0.004902391694486141, -0.0018780858954414725, 0... |
266 | LLY | 2017 | Capital expenditures of $1.08 billion during 2017 were $39.8 million more than in 2016. We expect 2018 capital expenditures to be approximately $1.2 billion. | [-0.0014119164552539587, -0.0026791859418153763, -0.011038181371986866, -0.014914724044501781, -0.009533851407468319, 0.00909026712179184, -0.0049437168054282665, -0.012304646894335747, 0.012799661606550217, -0.0031806291081011295, 0.004242981784045696, 0.03265810385346413, -0.006737340707331896, -0.0016682633431628346... |
267 | LLY | 2017 | In 2017, we repurchased $359.8 million of shares under the $5.00 billion share repurchase program previously announced in October 2013. See Note 12 to the consolidated financial statements for additional details. | [-0.0260041244328022, -0.0149654820561409, -0.00996419694274664, -0.039063744246959686, -0.02691228687763214, -0.008320552296936512, -0.03647996112704277, -0.014313140884041786, 0.006296374835073948, 0.01220262423157692, 0.00670248968526721, 0.02000514045357704, 0.010431068949401379, -0.02162959799170494, 0.00447365595... |
268 | LLY | 2017 | See "Results of Operations - Executive Overview - Other Matters - Patent Matters" for information regarding recent and upcoming losses of patent protection. | [-0.023348508402705193, -0.020613284781575203, 0.01810269244015217, -0.033615510910749435, -0.017362728714942932, 0.011099460534751415, -0.0019093715818598866, 0.003255511401221156, -0.019318347796797752, -0.004568617325276136, 0.019503338262438774, 0.020586857572197914, -0.009262763895094395, 0.0014757988974452019, 0.... |
269 | LLY | 2017 | Pursuant to the 2017 Tax Act, the U.S. will transition to a territorial tax system effective January 1, 2018; therefore, we expect that future repatriations of cash from our foreign subsidiaries to the U.S. will result in immaterial or no tax payments. This change in tax law provides us with additional liquidity in the... | [-0.017161792144179344, -0.022308995947241783, 0.010447757318615913, -0.02314908243715763, -0.012868009507656097, -0.004100427962839603, -0.020108764991164207, -0.017068447545170784, 0.0005488072638399899, -0.008507554419338703, 0.028376294299960136, 0.014174812473356724, -0.005640588700771332, 0.01862861029803753, 0.0... |
270 | LLY | 2017 | Both domestically and abroad, we continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government-backed agencies and suppliers; the uncertain impact of health care legislation; and various international government funding l... | [-0.018928347155451775, -0.029676472768187523, 0.005056384019553661, -0.01568537950515747, 0.005837343633174896, 0.017737053334712982, 0.00564541295170784, 0.017048750072717667, 0.0019209625897929072, -0.024553906172513962, 0.004579865839332342, 0.009867890737950802, -0.0020764926448464394, -0.007683850359171629, -0.00... |
271 | LLY | 2017 | In the normal course of business, our operations are exposed to fluctuations in interest rates and currency values. These fluctuations can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financ... | [-0.018712053075432777, -0.033950138837099075, 0.005237269680947065, -0.0030824884306639433, -0.027475927025079727, 0.014764362946152687, -0.024804655462503433, 0.002824243623763323, 0.002093920949846506, -0.01873837225139141, -0.009040211327373981, 0.029344500973820686, 0.007783529814332724, 0.015619696117937565, -0.0... |
272 | LLY | 2017 | Our primary interest rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest rate exposures, we strive to achieve an acceptable balance between fixed and floating rate debt positions and may enter into interest rate derivatives to help maintain that balance. Bas... | [-0.03032572939991951, -0.027306172996759415, 0.010496867820620537, -0.01905445009469986, -0.011713800951838493, 0.008616151288151741, -0.03813493251800537, 0.011193187907338142, -0.014056561514735222, -0.00889598112553358, 0.013379763811826706, 0.02293301932513714, 0.004639966879040003, 0.02777472510933876, -0.0026941... |
273 | LLY | 2017 | Our foreign currency risk exposure results from fluctuating currency exchange rates, primarily the U.S. dollar against the euro, Japanese yen, and British pound; and the Swiss Franc against the euro. We face foreign currency exchange exposures when we enter into transactions arising from subsidiary trade and loan payab... | [-0.002477187430486083, -0.02485319972038269, -0.001057236921042204, -0.015419392846524715, -0.019166890531778336, 0.008067530579864979, -0.016863740980625153, -0.009882724843919277, 0.005757874809205532, -0.004781963769346476, -0.0028106234967708588, 0.0284185279160738, -0.002270619384944439, 0.01639530435204506, 0.00... |
274 | LLY | 2017 | We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources. We acquire and coll... | [-0.008406060747802258, -0.015584959648549557, 0.008596953004598618, -0.01273521687835455, -0.0087196696549654, 0.019075555726885796, -0.013491966761648655, -0.0076697636395692825, -0.006128993351012468, -0.012128452770411968, 0.028415622189641, 0.028961028903722763, -0.0019719814881682396, 0.012033007107675076, -0.010... |
275 | LLY | 2017 | Individually, these arrangements are generally not material in any one annual reporting period. However, if milestones for multiple products covered by these arrangements were reached in the same reporting period, the aggregate charge to expense could be material to the results of operations or cash flows in that perio... | [-0.007074209861457348, -0.01935535855591297, 0.011130000464618206, -0.03247309848666191, -0.016116080805659294, 0.010293410159647465, -0.012455159798264503, -0.02856454811990261, -0.005183515138924122, -0.03410612419247627, 0.03199122101068497, 0.04679552838206291, -0.01068158820271492, 0.01376024167984724, -0.0091891... |
276 | LLY | 2017 | (1) Our long-term debt obligations include both our expected principal and interest obligations and our interest rate swaps. We used the interest rate forward curve at December 31, 2017, to compute the amount of the contractual obligation for interest on the variable rate debt instruments and swaps. | [-0.013022167608141899, -0.004751857835799456, -0.00553734228014946, -0.013106558471918106, -0.00414489209651947, 0.0044142939150333405, -0.029368039220571518, 0.020059071481227875, -0.015995323657989502, -0.00531662767753005, 0.03352266922593117, 0.029965266585350037, -0.015501962043344975, 0.009432307444512844, -0.00... |
277 | LLY | 2017 | •Purchase obligations consisting primarily of all open purchase orders as of December 31, 2017. Some of these purchase orders may be cancelable; however, for purposes of this disclosure, we have not distinguished between cancelable and noncancelable purchase obligations. | [-0.010435475036501884, -0.0208449587225914, -0.013762351125478745, 0.007537453901022673, -0.029006201773881912, -0.015399797819554806, -0.04057229310274124, 0.0010697011603042483, -0.026459062471985817, -0.007219061255455017, 0.028304439038038254, 0.0272647887468338, -0.01610156148672104, 0.011845498345792294, -0.0063... |
278 | LLY | 2017 | •Contractual payment obligations with each of our significant vendors, which are noncancelable and are not contingent. | [-0.0037335280794650316, -0.010332473553717136, -0.0022273887880146503, -0.0076563432812690735, 0.006781705655157566, 0.0002447680162731558, -0.03456776961684227, -0.00228776503354311, 0.009353401139378548, -0.020194992423057556, 0.01686614751815796, 0.03616039454936981, -0.00990820862352848, 0.014620808884501457, -0.0... |
279 | LLY | 2017 | (3) The 2017 Tax Act provides an election to taxpayers subject to the Toll Tax to make payments over an eight-year period. We intend to make this election; therefore, we have included future Toll Tax payments accordingly. The amounts shown reflect the provisional amount of Toll Tax recorded at December 31, 2017; these ... | [-0.024131322279572487, -0.029299501329660416, 0.005986803211271763, -0.029904428869485855, -0.01716151274740696, -0.0070224120281636715, -0.0430024079978466, -0.010980737395584583, -0.01875273324549198, -0.005648175720125437, 0.019857382401823997, 0.006243239622563124, -0.005118865054100752, 0.01408427581191063, 0.013... |
280 | LLY | 2017 | (4) We have included long-term liabilities consisting primarily of our nonqualified supplemental pension funding requirements and other post-employment benefit liabilities. We excluded long-term income taxes payable of $830.9 million, because we cannot reasonably estimate the timing of future cash outflows associated w... | [-0.003014967544004321, -0.009240679442882538, 0.010519756935536861, -0.044663283973932266, -0.02315390668809414, -0.008692503906786442, -0.02928825467824936, 0.0025271561462432146, -0.023662926629185677, 0.019864849746227264, 0.01540113240480423, 0.018820706754922867, -0.005837420932948589, 0.022370796650648117, -0.00... |
281 | LLY | 2017 | The contractual obligations table is current as of December 31, 2017. We expect the amount of these obligations to change materially over time as new contracts are initiated and existing contracts are completed, terminated, or modified. | [-0.009021849371492863, -0.02425285428762436, -0.018892815336585045, -0.022952647879719734, -0.02844536118209362, 0.0031128698028624058, -0.05402495712041855, 0.02370889112353325, -0.012325438670814037, -0.01988787204027176, 0.04256190359592438, 0.01349297259002924, -0.012265735305845737, 0.015721900388598442, 0.005721... |
282 | LLY | 2017 | In preparing our financial statements in accordance with accounting principles generally accepted in the U.S., we must often make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. Some of those judgments can be subjective and complex, and con... | [-0.00988724734634161, -0.012600883841514587, -8.185949263861403e-05, -0.043418191373348236, -0.0022510853596031666, -0.004612533841282129, -0.022994503378868103, 0.00744627183303237, -0.004940377548336983, -0.02459152415394783, 0.013542217202484608, 0.016827145591378212, -0.019826428964734077, 0.015411900356411934, -0... |
283 | LLY | 2017 | We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership. Provisions for returns, rebates, and discounts are established in the same period the related sales are recorded. | [0.0016579986549913883, -0.03524021431803703, -0.004307209979742765, -0.025119412690401077, -0.003144817426800728, -0.014320413582026958, -0.0021063266322016716, -0.00233293604105711, 0.00429416773840785, -0.0297885462641716, 0.010622929781675339, 0.03265784680843353, -0.014411709271371365, 0.01028383057564497, 0.00792... |
284 | LLY | 2017 | We regularly review the supply levels of our significant products sold to major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We... | [-0.011065724305808544, -0.011505109257996082, 0.005526102613657713, -0.0010198785457760096, -0.013499237596988678, 0.007138304878026247, -0.0021935414988547564, -0.0008652490796521306, 0.016426213085651398, -0.023699713870882988, 0.005079958587884903, 0.018873244524002075, -0.008699809201061726, 0.02382138930261135, 0... |
285 | LLY | 2017 | When sales occur, we estimate a reserve for future product returns related to those sales. This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventor... | [-0.006131760310381651, -0.020993947982788086, -0.010544718243181705, -0.004102618433535099, -0.019984491169452667, -0.010251429863274097, 0.004788093268871307, -0.0028800175059586763, -0.005047277547419071, 0.00624771136790514, 0.01676514744758606, 0.042724523693323135, -0.011567815206944942, 0.018947754055261612, -0.... |
286 | LLY | 2017 | We establish sales rebate and discount accruals in the same period as the related sales. The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medi... | [-0.006510129198431969, -0.007705595809966326, 0.017236026003956795, -0.02430892363190651, -0.009756868705153465, 0.0012454161187633872, -0.0034498691093176603, -0.008864431641995907, -0.010729226283729076, -0.013333277776837349, 0.012680599465966225, 0.027465753257274628, -0.018847741186618805, 0.003603048622608185, -... |
287 | LLY | 2017 | The largest of our sales rebate and discount amounts are rebates associated with sales covered by managed care, Medicare, and Medicaid contracts. In determining the appropriate accrual amount, we consider our historical managed care, Medicare, and Medicaid rebate payments by product as a percentage of our historical sa... | [-0.006300732027739286, 0.0020951952319592237, 0.01059546135365963, -0.04103553667664528, -0.0023526770528405905, 0.00028083191136829555, -0.013591001741588116, 0.007047933991998434, -0.013813142664730549, -0.022469917312264442, 0.028003253042697906, 0.042920369654893875, -0.013113061897456646, 0.00967323873192072, -0.... |
288 | LLY | 2017 | Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. A best estimate of these rebates, ... | [0.007605026941746473, -0.022889045998454094, -0.0036781164817512035, -0.021961111575365067, -0.014241774566471577, -0.013347460888326168, -0.0018978946609422565, 0.007584854494780302, -0.021060073748230934, 0.002291258191689849, 0.01322642620652914, 0.01807454600930214, -0.02381698042154312, 0.0024778535589575768, -0.... |
289 | LLY | 2017 | We believe that our accruals for sales returns, rebates, and discounts are reasonable and appropriate based on current facts and circumstances. Our global rebate and discount liabilities are included in sales rebates and discounts on our consolidated balance sheet. Our global sales return liability is included in other... | [-0.026507150381803513, -0.008930605836212635, -0.003364700125530362, -0.029393544420599937, -0.025699490681290627, -0.007123300340026617, -0.024666745215654373, 0.0057098944671452045, -0.0005867123254574835, -0.014365763403475285, 0.029499467462301254, 0.028095990419387817, -0.02307790331542492, 0.008387751877307892, ... |
290 | LLY | 2017 | The portion of our global sales return, rebate, and discount liability resulting from sales of our products in the U.S. was 87 percent and 85 percent as of December 31, 2017 and 2016, respectively. | [0.002616756595671177, -0.018259430304169655, -0.011026381514966488, -0.027672039344906807, -0.024881688877940178, -0.008743952959775925, -0.012209387496113777, 0.011701466515660286, 0.0069437273778021336, -0.016202030703425407, 0.022425666451454163, 0.03232690691947937, -0.026013260707259178, -0.012164381332695484, 0.... |
291 | LLY | 2017 | The following represents a roll-forward of our most significant U.S. pharmaceutical sales return, rebate, and discount liability balances, including managed care, Medicare, and Medicaid: | [-0.018536480143666267, -0.02006775513291359, 0.001084652729332447, -0.019691651687026024, -0.015567957423627377, -0.002107181353494525, -0.017690250650048256, 0.02360043302178383, -0.015675414353609085, -0.007542198523879051, 0.029255401343107224, 0.0379326231777668, -0.005675117950886488, 0.014130708761513233, 0.0064... |
292 | LLY | 2017 | (1) Adjustments of the estimates for these returns, rebates, and discounts to actual results were approximately 1 percent of consolidated net sales for each of the years presented. | [-0.019805772230029106, -0.018078980967402458, 0.006151693873107433, -0.005409304518252611, -0.013565776869654655, -0.005585907958447933, -0.0022615077905356884, -0.012591186910867691, 0.0006737102521583438, -0.026320485398173332, 0.017908919602632523, 0.05724574625492096, -0.011047539301216602, 0.0170455239713192, -0.... |
293 | LLY | 2017 | Product litigation liabilities and other contingencies are, by their nature, uncertain and based upon complex judgments and probabilities. The factors we consider in developing our product litigation liability reserves and other contingent liability amounts include the merits and jurisdiction of the litigation, the nat... | [0.023645874112844467, -0.007868369109928608, 0.0016536824405193329, -0.015464945696294308, 0.0017785367090255022, 0.006930687464773655, -0.007059788331389427, 0.01999027654528618, -0.02622789517045021, -0.018604138866066933, 0.008751691319048405, 0.016253141686320305, -0.018848752602934837, 0.016266731545329094, -0.01... |
294 | LLY | 2017 | We also consider the insurance coverage we have to diminish the exposure for periods covered by insurance. In assessing our insurance coverage, we consider the policy coverage limits and exclusions, the potential for denial of coverage by the insurance company, the financial condition of the insurers, and the possibili... | [-0.002140843542292714, -0.005563165992498398, 0.015323932282626629, -0.03898924961686134, -0.028656695038080215, 0.017355462536215782, 0.0012966145295649767, 0.021875957027077675, 0.010574724525213242, -0.008812270127236843, -0.00814630463719368, 0.03436112776398659, 0.007735962513834238, -0.0069892737083137035, 0.003... |
295 | LLY | 2017 | The litigation accruals and environmental liabilities and the related estimated insurance recoverables have been reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. | [-0.00859388429671526, -0.01836732216179371, 0.010628936812281609, -0.0239669568836689, -0.014802739024162292, -0.000285166606772691, -0.009501232765614986, 0.0005504849832504988, -0.00650374311953783, -0.02417435124516487, 0.0265334565192461, 0.01220383495092392, 0.011737198568880558, 0.011277043260633945, 0.000613270... |
296 | LLY | 2017 | We review the carrying value of long-lived assets (both intangible and tangible) for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset (or asset group) may not be recoverable. We identify impairment by comparing the projected undiscounted ca... | [-0.014635228551924229, -0.006287241820245981, 0.020528698340058327, -0.0207518357783556, -0.006969781592488289, 0.0038195978850126266, -0.007133853621780872, 0.016997866332530975, 0.009076466783881187, -0.004420101642608643, -0.00495169498026371, 0.029874242842197418, -0.012416974641382694, 0.0231275986880064, -0.0088... |
297 | LLY | 2017 | Goodwill and indefinite-lived intangible assets are reviewed for impairment at least annually and when certain impairment indicators are present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. | [-0.009156637825071812, -0.015621662139892578, 0.017257235944271088, -0.01961400732398033, -0.015840597450733185, 0.006197794806212187, -0.030728183686733246, -0.00021289827418513596, 0.005186829715967178, -0.015570147894322872, -0.0013506363611668348, 0.03018728457391262, -0.003548036329448223, 0.0203094482421875, -0.... |
298 | LLY | 2017 | Several methods may be used to determine the estimated fair value of acquired IPR&D, all of which require multiple assumptions. We utilize the “income method,” as described in Note 8 to the consolidated financial statements. | [-0.019772466272115707, -0.021675419062376022, 0.017178714275360107, -0.03339292109012604, -0.0030776357743889093, 0.012532120570540428, -0.03375786915421486, -0.0006745057180523872, 0.0034214055631309748, -0.007520575542002916, 0.0071295578964054585, 0.021714521571993828, 0.011567609384655952, 0.012036831118166447, -0... |
299 | LLY | 2017 | For acquired IPR&D assets, the risk of failure has been factored into the fair value measure and there can be no certainty that these assets ultimately will yield a successful product, as discussed previously in “Results of Operations - Executive Overview - Late-Stage Pipeline." The nature of the pharmaceutical busines... | [-0.005616641603410244, -0.01617538556456566, 0.000860122381709516, -0.030913561582565308, -0.009958776645362377, 0.01974129118025303, -0.01824984885752201, 0.013673827052116394, -0.005108194891363382, 0.0035455685574561357, 0.021083591505885124, 0.015144933015108109, -0.0070572406984865665, 0.009409653954207897, -0.00... |
300 | LLY | 2017 | Estimates of future cash flows, based on what we believe to be reasonable and supportable assumptions and projections, require management’s judgment. Actual results could vary materially from these estimates. | [-0.016465498134493828, -0.03777601942420006, -0.0031274985522031784, -0.031921617686748505, -0.005150988232344389, -0.006794384215027094, -0.02904488705098629, 0.0063370089046657085, -0.007381085772067308, -0.0010527509730309248, -0.0077785286121070385, 0.006065738387405872, -0.04231822490692139, 0.02012449875473976, ... |
301 | LLY | 2017 | Defined benefit pension plan and retiree health benefit plan costs include assumptions for the discount rate, expected return on plan assets, and retirement age. These assumptions have a significant effect on the amounts reported. In addition to the analysis below, see Note 14 to the consolidated financial statements f... | [-0.01156223937869072, -0.00790795311331749, 0.008365544490516186, -0.040087588131427765, -0.012335633859038353, 0.025599339976906776, -0.011729808524250984, -0.015171411447227001, -0.033591076731681824, -0.0004350341041572392, -0.005948688369244337, 0.03691667318344116, -0.02630828507244587, 0.011368891224265099, -0.0... |
302 | LLY | 2017 | Annually, we evaluate the discount rate and the expected return on plan assets in our defined benefit pension and retiree health benefit plans. We use an actuarially determined, plan-specific yield curve of high quality, fixed income debt instruments to determine the discount rates. In evaluating the expected return on... | [-0.027623191475868225, -0.020240217447280884, 0.007906542159616947, -0.043608590960502625, -0.0035821341443806887, 0.01974978670477867, -0.02126084454357624, 2.51603455581062e-06, -0.026006095111370087, -0.006050857715308666, -0.000350633286871016, 0.03602679446339607, 0.0029757230076938868, 0.0262314286082983, -0.013... |
303 | LLY | 2017 | If the 2017 discount rate for the U.S. defined benefit pension and retiree health benefit plans (U.S. plans) were to change by a quarter percentage point, income before income taxes would change by $30.0 million. As of January 1, 2016, we changed the method used to estimate the service and interest cost components of t... | [-0.032198697328567505, -0.00523531436920166, 0.015857253223657608, -0.03421615809202194, 0.0010314275277778506, -0.003090079640969634, -0.008688537403941154, -0.010161284357309341, -0.026832247152924538, -0.011788704432547092, 0.0047914725728333, 0.04828459396958351, -0.001936763641424477, 0.02047051675617695, -0.0154... |
304 | LLY | 2017 | If the 2017 expected return on plan assets for U.S. plans were to change by a quarter percentage point, income before income taxes would change by $23.7 million. If our assumption regarding the 2017 expected age of future retirees for U.S. plans were adjusted by one year, our income before income taxes would be affecte... | [-0.01241441909223795, -0.027770141139626503, 0.004935294855386019, -0.03174487501382828, 0.008923277258872986, 0.0007229047478176653, -0.027293173596262932, 0.0001499841018812731, -0.027823137119412422, 0.015408718958497047, 0.02007240615785122, 0.04152271896600723, -0.007472499739378691, 0.024497609585523605, 0.00995... |
305 | LLY | 2017 | We prepare and file tax returns based upon our interpretation of tax laws and regulations and record estimates based on these judgments and interpretations. In the normal course of business, our tax returns are | [0.0021563919726759195, -0.03724910318851471, -0.0033276465255767107, -0.033732131123542786, -0.024362094700336456, -0.0006963349296711385, -0.01521026436239481, 0.0007889923872426152, 0.002515790518373251, -0.013259243220090866, 0.019741255789995193, 0.006125821731984615, -0.012739398516714573, 0.012027019634842873, -... |
306 | LLY | 2017 | subject to examination by various taxing authorities, which may result in future tax, interest, and penalty assessments by these authorities. Inherent uncertainties exist in estimates of many tax positions due to changes in tax law resulting from legislation, regulation, and/or as concluded through the various jurisdic... | [-0.010652410797774792, -0.02866896614432335, 0.00891310814768076, -0.04056186228990555, -0.00890654418617487, 0.0018984656780958176, -0.02877398021519184, -0.02811763994395733, -0.020307183265686035, -0.010974017903208733, 0.038829121738672256, 0.0010936278849840164, -0.013651887886226177, 0.02651616744697094, -0.0198... |
307 | LLY | 2017 | We have recorded valuation allowances against certain of our deferred tax assets, primarily those that have been generated from net operating losses and tax credit carryforwards in certain taxing jurisdictions. In evaluating whether we would more likely than not recover these deferred tax assets, we have not assumed an... | [-0.02077649161219597, -0.025346795096993446, 0.010086185298860073, -0.02763194590806961, -0.005033242981880903, 0.007039316929876804, -0.016797175630927086, -0.013330049812793732, -0.010132151655852795, 0.008746613748371601, 0.03254370763897896, 0.009219404309988022, -0.008871378377079964, 0.018543872982263565, -0.007... |
308 | LLY | 2017 | The 2017 Tax Act was enacted in December 2017 and introduced numerous significant changes to the U.S. corporate income tax system. In accordance with GAAP, we recorded an estimate of the changes to our U.S. federal and state income tax expense that resulted from the 2017 Tax Act, which included re-measuring deferred ta... | [-0.021642480045557022, -0.02132556587457657, -0.0016027187230065465, -0.04180603474378586, -0.010946684516966343, -0.013033024035394192, -0.024045731872320175, -0.0064042722806334496, -0.015555119141936302, -0.018499763682484627, 0.027439335361123085, 0.008649068884551525, 0.0022414952982217073, 0.020454058423638344, ... |
309 | LLY | 2017 | As of December 31, 2017, a 5 percent change in the amount of the provisional charge related to the 2017 Tax Act, uncertain tax positions, and the valuation allowance would result in a change in net income of $95.7 million, $33.5 million, and $35.5 million, respectively. | [-0.012488452717661858, -0.03238420933485031, 0.013904936611652374, -0.03482731804251671, -0.0126638887450099, -0.012059608474373817, -0.04116901010274887, -0.020181652158498764, -0.02923935279250145, -0.0070824213325977325, 0.03662066534161568, 0.010942015796899796, -0.001047743484377861, 0.036126844584941864, 0.00357... |
310 | LLY | 2017 | To determine whether acquisitions or licensing transactions should be accounted for as a business combination or as an asset acquisition, we make certain judgments, which include assessing whether the acquired set of activities and assets would meet the definition of a business under the relevant accounting rules. | [-0.0004107686399947852, -0.009216103702783585, 0.031712714582681656, -0.04351761192083359, -0.017383744940161705, 0.008756592869758606, -0.008297082036733627, -0.008284137584269047, 0.016361171379685402, -0.03021121583878994, -0.00862068124115467, 0.027156438678503036, 0.002797514433041215, 0.0061775073409080505, 0.00... |
311 | LLY | 2017 | If the acquired set of activities and assets meets the definition of a business, assets acquired and liabilities assumed are required to be recorded at their respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets, where applicable, is recorded ... | [-0.013091547414660454, -0.009063378907740116, 0.012177873402833939, -0.029744422063231468, -0.008296426385641098, 0.017859991639852524, -0.011530965566635132, -0.005765482783317566, 0.016552837565541267, -0.01350503508001566, 0.00884996633976698, 0.027530264109373093, 0.006779193878173828, 0.014565430581569672, -0.002... |
312 | LLY | 2017 | operations. The fair values of intangible assets, including acquired IPR&D, are determined using information available near the acquisition date based on expectations and assumptions that are deemed reasonable by management. Depending on the facts and circumstances, we may deem it necessary to engage an independent val... | [-0.0029082889668643475, -0.00698648439720273, 0.0034075588919222355, -0.031531453132629395, -0.01397296879440546, 0.020933089777827263, -0.02918504923582077, -0.003158747684210539, 0.01276681199669838, -0.011481561698019505, 0.014829801395535469, 0.016306191682815552, -0.023226765915751457, 0.009260387159883976, -0.00... |
313 | LLY | 2017 | The fair values of identifiable intangible assets are primarily determined using an "income method," as described in Note 8 to the consolidated financial statements. | [-0.0315922386944294, -0.014844847843050957, 0.0140437763184309, -0.02691098116338253, -0.010182363912463188, 0.004696904681622982, -0.055774569511413574, -0.005961094982922077, 0.014294111169874668, -0.02244250662624836, 0.014369212090969086, 0.0273866169154644, 0.000965353159699589, 0.014469346031546593, -0.017360711... |
314 | LLY | 2017 | The fair value of any contingent consideration liability that results from a business combination is determined using a market approach based on quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or a discounted cash flow analysis. Estimating the fair value of c... | [-0.024502158164978027, -0.026152966544032097, 0.009781365282833576, -0.014597306959331036, -0.0004655084921978414, -0.013843393884599209, -0.03621380031108856, -0.01576717011630535, -0.01211459469050169, -0.027270836755633354, -0.001891280640847981, 0.0394374243915081, -0.03842354193329811, 0.028232725337147713, -0.00... |
315 | LLY | 2017 | As of December 31, 2017, a 5 percent change in the contingent consideration liability would result in a change in income before income taxes of $12.7 million. | [-0.02044677734375, -0.014169486239552498, 0.009793614968657494, -0.02449706196784973, 0.009168490767478943, -0.016826264560222626, -0.03914841637015343, -0.015589039772748947, -0.01858442649245262, -0.00256073079071939, 0.030500860884785652, 0.03823677450418472, -0.0008481505210511386, 0.02431473322212696, 0.015654155... |
316 | LLY | 2017 | Information relating to certain legal proceedings can be found in Note 15 to the consolidated financial statements and is incorporated here by reference. | [-0.02032831870019436, -0.008738274686038494, 0.008731964975595474, -0.026624923571944237, 0.004072603769600391, -0.0009629452251829207, -0.012801414355635643, -0.012788795866072178, -0.0038707086350768805, -0.015192610211670399, 0.023785771802067757, 0.009501690976321697, -0.008612089790403843, 0.01750178635120392, 0.... |
317 | LLY | 2017 | For the full year of 2018, we expect EPS to be in the range of $4.39 to $4.49, which reflects the estimated impact of the 2017 Tax Act. We anticipate that total revenue will be between $23.0 billion and $23.5 billion. Revenue growth is expected to be driven by new products including Trulicity, Taltz, Basaglar, Jardianc... | [-0.012382501736283302, -0.02285105176270008, 0.0071579269133508205, -0.022476019337773323, 0.030959488824009895, -0.0031214896589517593, -0.018169624730944633, -0.0180661678314209, -0.03152850270271301, -0.008483468554913998, 0.02283811941742897, 0.02653670497238636, -0.015169373713433743, 0.0005055649671703577, 0.012... |
318 | LLY | 2017 | We anticipate that gross margin as a percent of revenue will be approximately 73 percent in 2018. Research and development expenses are expected to be in the range of $5.0 billion to $5.2 billion. Marketing, selling, and administrative expenses are expected to be in the range of $6.1 billion to $6.4 billion. Other—net,... | [-0.004286039154976606, -0.014593786559998989, -0.005944423843175173, -0.022425226867198944, 0.011186852119863033, 0.0027097684796899557, -0.012526440434157848, -0.006140854209661484, -0.022695720195770264, 0.004450267646461725, 0.034107983112335205, 0.04456707835197449, -0.009493045508861542, -0.009196789935231209, 0.... |
319 | LLY | 2017 | The 2018 tax rate is expected to be approximately 18.0 percent and reflects the estimated impact of the 2017 Tax Act. Refer to “Results of Operations - Executive Overview - Other Matters - Tax Matters” for further discussion of the 2017 Tax Act. The 2018 tax rate benefits from a lower corporate income tax rate, partial... | [-0.03272843733429909, -0.019931592047214508, 0.006493636406958103, -0.05316783860325813, -0.010137182660400867, -0.013812466524541378, -0.010029272176325321, -0.015729453414678574, -0.023257756605744362, -0.0074267396703362465, 0.007890117354691029, 0.02448919788002968, -0.0053859734907746315, 0.014409144409000874, -0... |
320 | LLY | 2017 | Capital expenditures are expected to be approximately $1.2 billion. | [0.004968106281012297, -0.0015241941437125206, -0.008605294860899448, -0.012350131757557392, -0.017915192991495132, 0.011704245582222939, -0.026879314333200455, -0.007939836010336876, 0.006687208078801632, 0.01105835847556591, 0.012813342735171318, 0.03392534703016281, -0.008507433347404003, 0.006791593972593546, 0.009... |
321 | LLY | 2017 | You can find quantitative and qualitative disclosures about market risk (e.g., interest rate risk) at Item 7, “Management’s Discussion and Analysis - Financial Condition.” That information is incorporated in this report by reference. | [-0.02659015916287899, -0.014509472995996475, -0.0038740418385714293, -0.030182739719748497, -0.02363007329404354, 0.006875238381326199, -0.04571685567498207, -0.012428558431565762, -0.008386905305087566, -0.019367046654224396, 0.012162909843027592, 0.04541325941681862, -0.010505769401788712, 0.002461993135511875, -0.0... |
null | Ticker | Year | Text | Embedding |
0 | LLY | 2018 | Eli Lilly and Company (the “company” or “registrant” or "Lilly") was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and market products in two business segments—human pharmaceutical products... | [-0.008317005820572376, -0.007572682108730078, -0.01593499444425106, -0.00765035068616271, -0.007119616027921438, 0.01571493409574032, -0.017100023105740547, 0.01388972345739603, -0.0024206694215536118, 0.010750619694590569, -0.008867157623171806, 0.010912429541349411, 0.021760134026408195, 0.004938424564898014, 0.0020... |
1 | LLY | 2018 | The mission of our human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Our vision is to make a significant contribution to humanity by improving global health in the 21st century. Most of the products we sell today were discovered or developed by our own scient... | [0.007174389902502298, -0.00886403489857912, 0.0025608676951378584, -0.007385595701634884, 0.005950057413429022, 0.009860660880804062, 0.0026021189987659454, 0.02564827911555767, -0.004841228015720844, 0.012203723192214966, -0.024394245818257332, 0.017292458564043045, -0.013754764571785927, -0.012454529292881489, -0.01... |
2 | LLY | 2018 | Our animal health business, Elanco Animal Health Incorporated (Elanco), develops, manufactures, and markets products for both food animals and companion animals. Elanco food animal products help the food industry produce an abundant supply of safe, nutritious, and affordable food. Elanco companion animal products help ... | [-0.003220034996047616, -0.013543135486543179, -0.010202409699559212, -0.015474190935492516, -0.004789017606526613, 0.010517815127968788, -0.003479118226096034, -0.013118303380906582, -0.021653568372130394, 0.005442358087748289, -0.010723794810473919, 0.011856680735945702, -0.005851098336279392, -0.02543843723833561, 0... |
3 | LLY | 2018 | In September 2018 Elanco completed an initial public offering of its common stock, which trades on the New York Stock Exchange under the symbol "ELAN." In February 2019, Elanco filed a registration statement to launch an exchange offer in which shareholders can exchange shares of Lilly common stock for Elanco common st... | [-0.03326813504099846, -0.015502848662436008, 0.0016413929406553507, -0.02861471101641655, -0.022714372724294662, -0.00343222264200449, -0.03463074192404747, 0.0011432707542553544, -0.02055477164685726, 0.009666784666478634, -0.002228695200756192, 0.0042967055924236774, 0.019115038216114044, -0.010855849832296371, 0.02... |
4 | LLY | 2018 | We manufacture and distribute our products through facilities in the United States (U.S.), Puerto Rico, and 13 other countries. Our products are sold in approximately 125 countries. | [-0.009576004929840565, -0.014729331247508526, -0.00854792632162571, -0.012259355746209621, -0.0007298390264622867, 0.017561398446559906, -0.0013837036676704884, 0.02552739344537258, 0.007558642886579037, 0.005486320238560438, -0.011767947115004063, 0.01026785746216774, -0.027855118736624718, -0.02445405349135399, -0.0... |
5 | LLY | 2018 | •Olumiant®, for the treatment of adults with moderately-to-severely active rheumatoid arthritis (approved in the European Union (EU) and Japan in 2017, and in the U.S. in 2018) | [0.00521065155044198, -0.012903176248073578, -0.013211006298661232, -0.02272806130349636, -0.010562391951680183, 0.0371447317302227, -0.014583411626517773, -0.0015656003961339593, -0.02429286018013954, -0.004659124184399843, 0.028371596708893776, -0.0122298002243042, -0.013127635233104229, -0.012935242615640163, -0.019... |
6 | LLY | 2018 | •Taltz®, for the treatment of moderate-to-severe plaque psoriasis (approved in the U.S. and EU in 2016) and active psoriatic arthritis (approved in Japan in 2016, in the U.S. in 2017, and in the EU in 2018) | [0.004236882086843252, -0.019787175580859184, 0.016844268888235092, -0.02473074197769165, -0.020174400880932808, 0.02940325252711773, -0.037276819348335266, -0.005072642117738724, -0.0022717174142599106, -0.015385722741484642, 0.02213633805513382, -0.007867112755775452, 0.0022910786792635918, -0.011726451106369495, -0.... |
7 | LLY | 2018 | •Emgality®, a once-monthly subcutaneously injected calcitonin gene-related peptide (CGRP) antibody for the treatment of migraine prevention (approved in the U.S. and EU in 2018). | [-0.024359017610549927, 0.001984283560886979, 0.00618542218580842, -0.02850242517888546, 0.0043545374646782875, 0.014000496827065945, -0.012436822056770325, -0.01933150552213192, -0.01070160511881113, -0.005090190097689629, 0.01385534554719925, 0.0027578736189752817, -0.006356964819133282, -0.017827210947871208, -0.016... |
8 | LLY | 2018 | •Lartruvo®, approved in the U.S., and conditionally approved in the EU, in 2016 for use in combination with another agent for the treatment of soft tissue carcinoma. Following a negative result in a recent | [-0.009103967808187008, -0.0024345105048269033, -0.012307710014283657, -0.02757888287305832, -0.002461208263412118, 0.018581705167889595, -0.007228443864732981, -0.022893408313393593, -0.027445392683148384, 0.006737870629876852, 0.02554984577000141, -0.00972469337284565, 0.0039312588050961494, -0.008303032256662846, -0... |
9 | LLY | 2018 | clinical trial, we are suspending promotion of Lartruvo and are working with global regulators to determine the appropriate next steps. | [-0.009115702472627163, -0.011495121754705906, -0.002663068939000368, -0.019566992297768593, -0.004366590175777674, 0.028397424146533012, -0.015417596325278282, 0.0018234647577628493, 0.0008209643419831991, -0.006846501957625151, 0.019385455176234245, -0.004950098693370819, -0.007086389232426882, -0.023042110726237297,... |
10 | LLY | 2018 | •Portrazza®, approved in the U.S. for use in combination with other agents as a first-line treatment of metastatic squamous NSCLC, and approved in the EU for use in combination with other agents as a first-line treatment for epidermal growth factor receptor expressing squamous NSCLC | [-0.02340087667107582, -0.008456950075924397, 0.019659921526908875, -0.027725528925657272, 0.008709000423550606, 0.006838521920144558, -0.015016889199614525, -0.015494458377361298, -0.030909322202205658, 0.0016449596732854843, 0.0026664265897125006, 0.003508805064484477, -0.02052219770848751, 0.00791305210441351, -0.00... |
11 | LLY | 2018 | •Verzenio®, approved in 2017 in the U.S. for use as a single agent and in combination with endocrine therapy for the treatment of a certain type of metastatic breast cancer | [-0.026200324296951294, -0.026607241481542587, -0.022577432915568352, -0.019230198115110397, 0.009923569858074188, 0.0218423530459404, -0.040035564452409744, -0.02412634901702404, -0.02869434282183647, -0.0065796151757240295, 0.018547624349594116, 0.011242774315178394, 0.0074820565059781075, -0.019177692010998726, -0.0... |
12 | LLY | 2018 | We sell most of our products worldwide. We adapt our marketing methods and product emphasis in various countries to meet local customer needs. | [-0.020673643797636032, -0.006993306800723076, 0.005120555404573679, -0.020737452432513237, -0.007261298596858978, 0.018210673704743385, 0.002000366570428014, 0.011364123784005642, 0.018887033686041832, -0.015364856459200382, -0.018465902656316757, 0.028253979980945587, -0.015186195261776447, -0.018912555649876595, -0.... |
13 | LLY | 2018 | Human Pharmaceuticals—U.S. | [0.002939702710136771, -0.012413954362273216, 0.009131483733654022, -0.01804683730006218, 0.010901045985519886, 0.006233993452042341, -0.007132282946258783, 0.010090558789670467, -0.01924905925989151, 0.0061732069589197636, 0.015304690226912498, 0.008895091712474823, -0.0018522997852414846, -0.01939764805138111, -0.010... |
14 | LLY | 2018 | In the U.S., most of our pharmaceutical products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. In 2018, 2017, and 2016, three wholesale distributors in the U.S. - McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc. - ... | [-0.00266223750077188, -0.003533124690875411, 0.0023532130289822817, -0.01180572621524334, -0.0019285110756754875, 0.032257527112960815, 0.005083204712718725, 0.00634574331343174, -0.0010080477222800255, -0.006193710025399923, 0.012903011403977871, 0.03550972044467926, -0.004319732543081045, 0.006405234802514315, -0.00... |
15 | LLY | 2018 | We promote our major human pharmaceutical products in the U.S. through sales representatives who call upon physicians and other health care professionals. We also promote to healthcare providers in medical journals and on-line health care channels, distribute literature and samples of certain products to physicians, an... | [-0.007460508029907942, 0.004420917946845293, 0.003084633033722639, -0.017683671787381172, 0.008748413063585758, 0.026158489286899567, 0.004480975680053234, 0.02933487668633461, 0.009649279527366161, 0.004057235084474087, 0.0008933591307140887, 0.00972935650497675, -0.007760796695947647, 0.006512930151075125, -0.022688... |
16 | LLY | 2018 | We maintain special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. We enter into arrangements with these organizations providing for discounts or rebates ... | [0.000447617843747139, -0.014522711746394634, -0.000883630767930299, -0.017851661890745163, -0.0308226328343153, 0.03206932917237282, 0.024297358468174934, 0.021246926859021187, 0.0051625254563987255, 0.0006067708600312471, 0.0033372396137565374, 0.027453893795609474, 0.007294512819498777, 0.0006676965858787298, -0.020... |
17 | LLY | 2018 | Human Pharmaceuticals—Outside the U.S. | [0.008997807279229164, -0.00992364902049303, 0.00925841461867094, -0.009916790761053562, 0.00984135176986456, 0.014648869633674622, -0.006045402027666569, 0.010026520118117332, -0.012687457725405693, 0.0044783297926187515, 0.008860645815730095, 0.005287583451718092, -0.00790737196803093, -0.012419992126524448, -0.00542... |
18 | LLY | 2018 | Outside the U.S, we promote our human pharmaceutical products to healthcare providers primarily through sales representatives and on-line health care channels. While the products marketed vary from country to country, endocrinology products constitute the largest single group in consolidated revenue. Distribution patte... | [0.0011148954508826137, -0.004186814185231924, 0.007525749504566193, -0.01656322181224823, 0.027421334758400917, 0.015248680487275124, -0.005471778567880392, 0.005172720644623041, -0.0005685391370207071, 0.003450671210885048, -0.0001114279220928438, 0.01697072945535183, 0.000603456690441817, -0.0010236991802230477, -0.... |
19 | LLY | 2018 | •We and Boehringer Ingelheim have a diabetes alliance under which we jointly develop and commercialize Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, and Basaglar in major markets. | [-0.01686611771583557, -0.03223244100809097, 0.021733874455094337, -0.014011245220899582, -0.0021707562264055014, 0.028417173773050308, -0.0159451924264431, -0.0008806363330222666, 0.00023434300965163857, -0.007854190655052662, 0.011116903275251389, 0.004420449025928974, -0.009525015950202942, -0.010577503591775894, 0.... |
20 | LLY | 2018 | •Outside the U.S. and Canada, Erbitux is commercialized by Merck KGaA. | [0.007230485789477825, -0.010561673901975155, -0.012918037362396717, -0.04077477380633354, -0.01380248088389635, 0.024544917047023773, -0.0059942021034657955, -0.02198842354118824, 0.017701778560876846, -0.0014202740276232362, 0.02184639684855938, 0.012001315131783485, -0.011013579554855824, -0.00903165154159069, -0.01... |
21 | LLY | 2018 | •We and Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) co-promote Effient in the U.S., Brazil, Mexico, and certain other countries. Effective January 2016, Daiichi Sankyo has been exclusively promoting Effient in major European markets; however, the economic results for these countries continue to be shared. We retain sole ... | [-0.028456157073378563, 0.009625650011003017, -0.0024113436229526997, -0.03384757414460182, -0.007692629937082529, 0.036819424480199814, -0.00036203028867021203, 0.001170331728644669, -0.012512030079960823, -0.012117535807192326, 0.007521682884544134, 0.006344776134938002, 0.0030096592381596565, -0.010131916962563992, ... |
22 | LLY | 2018 | For additional information, see Item 8, "Financial Statements and Supplementary Data - Note 4, Collaborations and Other Arrangements." | [-0.01744447648525238, -0.013937662355601788, -0.00947735458612442, -0.052781376987695694, -0.024291720241308212, 0.010616429150104523, -0.018301980569958687, -0.004380316939204931, 0.004930655937641859, -0.020477741956710815, 0.019146688282489777, 0.020362554118037224, -0.00838947482407093, 0.009374965913593769, -0.00... |
23 | LLY | 2018 | Our Elanco animal health business unit employs field salespeople throughout the U.S. and has an extensive sales force outside the U.S. Elanco sells its products primarily to wholesale distributors, and promotes its products primarily to producers and veterinarians for food animal products and to veterinarians for compa... | [-0.01915886625647545, -0.016797874122858047, -0.017055906355381012, -0.0019045977387577295, -0.0034576270263642073, 0.02615153044462204, -0.0019642675761133432, 0.00020380485511850566, -0.011624336242675781, -0.003947887569665909, -0.0075280796736478806, 0.01024386566132307, -0.015636730939149857, -0.01506906095892191... |
24 | LLY | 2018 | Our human pharmaceutical products compete globally with products of many other companies in highly competitive markets. Our animal health products compete globally with products of animal health care companies as well as pharmaceutical, chemical, and other companies that operate animal health businesses. | [-0.002152522560209036, -0.0046298922970891, -0.00010971794108627364, 0.00037447657086886466, -0.0032386276870965958, 0.022640861570835114, 0.0016250560292974114, 0.018414568156003952, -0.020015833899378777, -0.0024101033341139555, -0.025016510859131813, 0.026709653437137604, -0.015212033875286579, -0.01809956505894661... |
25 | LLY | 2018 | Important competitive factors for both human pharmaceutical and animal health products include effectiveness, safety, and ease of use; price and demonstrated cost-effectiveness; marketing effectiveness; and research and development of new products, processes, and uses. Most new products that we introduce must compete w... | [-0.0002840037923306227, -0.0013371673412621021, -0.004590226802974939, -0.003670202801004052, 0.004441835917532444, 0.022146524861454964, 0.002400635741651058, -0.0055597140453755856, -0.026446564123034477, -0.018123481422662735, -0.010585220530629158, 0.01663297601044178, -0.008824314922094345, -0.007379976566880941,... |
26 | LLY | 2018 | We believe our long-term competitive success depends upon discovering and developing (either alone or in collaboration with others) or acquiring innovative, cost-effective human pharmaceutical and animal health products that provide improved outcomes and deliver value to payers, and continuously improving the productiv... | [-0.018223093822598457, -0.006291783880442381, 0.004963852930814028, -0.012730744667351246, -0.015908412635326385, 0.03170979022979736, -0.008014414459466934, 0.01644359901547432, -0.02511361800134182, 0.01407539937645197, -0.007318672724068165, 0.021153239533305168, 0.003906860016286373, -0.012081830762326717, -0.0222... |
27 | LLY | 2018 | One of the biggest competitive challenges we face is from generic pharmaceuticals. In the U.S. and the EU, the regulatory approval process for human pharmaceuticals (other than biological products (biologics)) exempts generics from costly and time-consuming clinical trials to demonstrate their safety and efficacy, allo... | [0.015911515802145004, -0.019677240401506424, -0.010183369740843773, 0.001465185428969562, 0.005741405300796032, 0.02084408514201641, 0.009454092010855675, 0.017502667382359505, -0.03248601034283638, -0.022302640601992607, 0.003180645639076829, -0.014108209870755672, -0.0013557936763390899, -0.017754599452018738, -0.00... |
28 | LLY | 2018 | generally invest far less than we do in research and development and can price their products much lower than our branded products. Accordingly, when a branded non-biologic human pharmaceutical loses its market exclusivity, it normally faces intense price competition from generic forms of the product. Public and privat... | [-0.0005626592319458723, -0.01444215327501297, -0.007710641250014305, -0.017107559368014336, 0.009961278177797794, 0.02888430655002594, 0.012137120589613914, 0.009077342227101326, -0.012640283443033695, -0.011382374912500381, -0.005595994181931019, 0.001597034279257059, 0.0001252596703125164, -0.02012654021382332, -0.0... |
29 | LLY | 2018 | Several of our current products, including Cyramza, Erbitux, Trulicity, Taltz, and Emgality and many of the new molecular entities (NMEs) in our research pipeline are biologics. Competition for Lilly’s biologics may be affected by the approval of follow-on biologics, also known as biosimilars. A biosimilar is a subsequ... | [-0.017414379864931107, -0.01456623338162899, -0.00895809754729271, -0.006499876268208027, -0.011609585955739021, 0.02389730140566826, -0.018987640738487244, -0.012355528771877289, -0.021062718704342842, -0.01622086949646473, 0.014484857209026814, -0.00661854911595583, -0.010449984110891819, -0.014064417220652103, 0.00... |
30 | LLY | 2018 | Biosimilars may present both competitive challenges and opportunities. For example, a competitor company has developed a version of insulin lispro which competes with our product Humalog. On the other hand, with our partner Boehringer Ingelheim, we developed Basaglar, a new insulin glargine product, which has the same ... | [-0.01368296705186367, -0.028573255985975266, 0.007599412463605404, -0.0038801943883299828, 0.006003066431730986, 0.024522023275494576, -0.004956721793860197, 0.0010815580608323216, -0.03401961177587509, -0.03302692621946335, -0.008652464486658573, 0.007485387846827507, -0.013602479360997677, -0.024629341438412666, 0.0... |
31 | LLY | 2018 | U.S. Private Sector Dynamics | [-0.0029493875335901976, -0.028236985206604004, 0.0036983562167733908, -0.02447664551436901, -0.011522066779434681, 0.009084044955670834, -0.02137746289372444, 0.02400832436978817, -0.008498643524944782, -0.027920179069042206, 0.005420123692601919, 0.010103330947458744, 0.022493168711662292, 0.009944927878677845, 0.004... |
32 | LLY | 2018 | In the U.S. private sector, consolidation and integration among healthcare providers is also a major factor in the competitive marketplace for human pharmaceuticals. Health plans and pharmacy benefit managers have been consolidating into fewer, larger entities, thus enhancing their purchasing strength and importance. F... | [0.01062620710581541, -0.004553156904876232, 0.02243962697684765, -0.014807544648647308, -0.024944515898823738, 0.02906714379787445, 0.0034083444625139236, 0.01178080402314663, -0.009014989249408245, -0.018356136977672577, 0.016516609117388725, 0.01660793274641037, 0.00881277211010456, 0.0021151304244995117, -0.0051598... |
33 | LLY | 2018 | Payers typically maintain formularies which specify coverage (the conditions under which drugs are included on a plan's formulary) and reimbursement (the associated out-of-pocket cost to the consumer). Formulary placement can lead to reduced usage of a drug for the relevant patient population due to coverage restrictio... | [0.007753089070320129, -0.009528708644211292, 0.0036901719868183136, -0.012409008108079433, -0.034753356128931046, 0.03196116164326668, 0.0038223271258175373, -0.013445916585624218, -0.029467159882187843, 0.0034495822619646788, 0.020304417237639427, 0.007637877017259598, -0.000478214438771829, 0.011765176430344582, -0.... |
34 | LLY | 2018 | Intellectual property protection is critical to our ability to successfully commercialize our life sciences innovations and invest in the search for new medicines. We own, have applied for, or are licensed under, a large number of patents in the U.S. and many other countries relating to products, product uses, formulat... | [0.0045174057595431805, 0.0043318928219377995, 0.012354518286883831, -0.04723097383975983, 0.006515739485621452, 0.023940948769450188, 0.0007103197276592255, 0.01911109872162342, 0.010056760162115097, -0.012100658379495144, 0.005236675497144461, 0.013207227922976017, -0.0002695228031370789, -0.0005020243697799742, -0.0... |
35 | LLY | 2018 | U.S., various European countries, and Japan. These patents may be issued based upon the filing of international patent applications, usually filed under the Patent Cooperation Treaty (PCT). Patent applications covering the compounds are generally filed during the Discovery Research Phase of the drug discovery process, ... | [0.01152475643903017, -0.005442245863378048, 0.02965017408132553, -0.04015842825174332, -0.0007582510588690639, 0.0067194742150604725, -0.005947196390479803, -0.00038160078111104667, -0.027485156431794167, 0.011386142112314701, 0.010910894721746445, 0.03197360783815384, -0.007247527129948139, 0.01000660378485918, -0.00... |
36 | LLY | 2018 | •Patent term adjustment is a statutory right available to all U.S. patent applicants to provide relief in the event that a patent grant is delayed during examination by the United States Patent and Trademark Office (USPTO). | [-0.009824693202972412, -0.015220982022583485, 0.019742196425795555, -0.03208604082465172, -0.018774311989545822, 0.00415991572663188, -0.005651518702507019, 0.007975105196237564, -0.022539781406521797, -0.0032500375527888536, 0.02492634765803814, 0.012781382538378239, -0.02051120065152645, 0.005578596144914627, -0.011... |
37 | LLY | 2018 | •Patent term restoration is a statutory right provided to U.S. patent holders that claim inventions subject to review by the U.S. Food and Drug Administration (FDA). To make up for a portion of the time invested in clinical trials and the FDA review process, a single patent for a human pharmaceutical product may be eli... | [0.011778779327869415, -0.01204739511013031, 0.011751918122172356, -0.010711033828556538, -0.004606752190738916, -0.0029581256676465273, 0.0008956640376709402, 0.0037337522953748703, -0.029332788661122322, 0.007957727648317814, 0.006194939836859703, 0.02143549919128418, -0.03661226108670235, 0.0024410414043813944, -0.0... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.